The recent emergence of the coronavirus SARS-CoV-2 and the COVID-19 pandemic has spurred global healthcare and life sciences companies, as well as government agencies, to partner at unprecedented speed to develop vaccines, treatments, and tests This article covers the last four months of deal data provided by Chris Dokomajilar of DealForma Our team at PharmaShots […]Read More
The recent emergence of the coronavirus SARS-CoV-2 and the COVID-19 pandemic has spurred global healthcare and life sciences companies, as well as government agencies, to partner at an unprecedented speed to develop vaccines, treatments, and tests This article covers last four months of deal data provided by Chris Dokomajilar of DealForma. This first part is […]Read More
The biopharma industry saw a significant increase in the number of deal terminations in the last two years. Clinical and regulatory results, change in control limitations, and strategic reprioritizations were among the most common reasons for deal termination. We used the DealForma database to track partnership terminations announced in 2018 and 2019. We compiled a […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
